Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376048 | 0.91 | — | — | |
| SCHEMBL6558915 | 0.91 | — | — | |
| SCHEMBL9282159 | 0.91 | AGTR1 (0.45) | — | |
| SCHEMBL8913338 | 0.89 | — | — | |
| SCHEMBL8914350 | 0.88 | — | — | |
| SCHEMBL27959183 | 0.85 | — | — | |
| SCHEMBL8029160 | 0.84 | GPR4 (0.52) | — | |
| SCHEMBL8384340 | 0.82 | AGTR1 (0.55) | — | |
| SCHEMBL9282165 | 0.82 | — | — | |
| SCHEMBL8327383 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1393722-A2 | Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome | DePadova, Anthony S. (US) | 2004-03-03 | — | — | EP | claimed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0569013-B1 | Quinoline compounds as angiotensin II antagonists | GREEN CROSS CORP (JP) | 1996-08-28 | — | — | EP | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0569013-A1 | Quinoline compounds as angiotensin II antagonists | THE GREEN CROSS CORPORATION (JP) | 1993-11-10 | — | — | EP | claimed |
| EP-1393722-A2 | Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome | DePadova, Anthony S. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6218414-B1 | ADMINISTERING AN EFFECTIVE AMOUNT OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY FOR THERAPY OF CARDIOVASCULAR COMPLAINTS | SANOFI (FR) | 2001-04-17 | — | — | US | disclosed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | disclosed |
| US-5665881-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE, ANGIOTENSIN II ANTAGONIST | THE GREEN CROSS CORPORATION (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0569013-B1 | Quinoline compounds as angiotensin II antagonists | GREEN CROSS CORP (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0693478-A1 | Quinoline compounds | THE GREEN CROSS CORPORATION (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-5478832-A | Angiotensin II antagonists; cardiovascular disorders | THE GREEN CROSS CORPORATION (JP) | 1995-12-26 | — | — | US | disclosed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0569013-A1 | Quinoline compounds as angiotensin II antagonists | THE GREEN CROSS CORPORATION (JP) | 1993-11-10 | — | — | EP | disclosed |